FXYD3 functionally demarcates an ancestral breast cancer stem cell subpopulation with features of drug-tolerant persisters
Mengjiao Li, Noriko Gotoh(Kanazawa University), Yasuto Takeuchi(Kanazawa University), Teppei Shimamura(Systems Biology Institute), Koji Okamoto(Teikyo University), Arinobu Tojo(Tokyo Medical and Dental University), Daisuke Shiokawa(Ehime University Hospital), Chia‐Chi Liu(National Taiwan University), Masafumi Inokuchi(Kanazawa University Hospital), Masahiko Tanabe(The University of Tokyo), Seitaro Nomura(The University of Tokyo), Toshinari Yamashita(Kanagawa Prefectural Hospital Organization), Luís Augusto Eijy Nagai(Quantitative BioSciences), Seishi Ogawa(Keio University), Masahiro Nakagawa(NTT (Japan)), Yutaka Suzuki(Kyorin University), Sumio Sugano(The University of Tokyo), Dominic Chih‐Cheng Voon(Kanazawa University), Keiichiro Tada(Nihon University), Theodoros Foukakis(Karolinska Institutet), Shinya Sato(Tokuyama (Japan)), Hiroshi Asahara(Scripps Research Institute), Tatsunori Nishimura, Tomoki Chiba(Tokyo Medical and Dental University), Akinori Kanai(Frontier Medical College), Satoko Ishikawa(Kanazawa University Hospital), Manami Katoh(The University of Tokyo), Yohei Miyagi(Kanagawa Cancer Center), Tetsu Akiyama(Quantitative BioSciences), Ryuichiro Nakato(Quantitative BioSciences), Haruka Hirose(Nagoya City University), Tsunaki Hongu(Kanazawa University), Kang Wang(Karolinska University Hospital), Yuming Wang(National Sun Yat-sen University), Xi Cheng(Jiangsu Cancer Hospital), Tetsuo Ota(Kanazawa University Hospital), Asako Sasahara(The University of Tokyo), Masao Yano(Oida Hospital), Y. UCHIDA(Systems Biology Institute)
Cited by 29
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
|Nature Genetics|2000|2k